Related Experiment Video

Updated: Jul 17, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction

Ibrahim F Benter1, Mariam H M Yousif, Constantin Cojocel

  • 1Dept. of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, P. O. Box 24923, Safat 13110, Kuwait. ibenter@hsc.edu.kw

American Journal of Physiology. Heart and Circulatory Physiology
|January 11, 2007
PubMed

Insights

Treatment with angiotensin-(1-7) [ANG-(1-7)] or its analog AVE-0991 protected against diabetes-induced cardiovascular dysfunction. These findings suggest a potential therapeutic strategy for diabetic patients to reduce cardiovascular events.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus is associated with significant cardiovascular complications.
  • Diabetic cardiovascular dysfunction involves alterations in vascular responsiveness and cardiac function.
  • The renin-angiotensin system plays a critical role in cardiovascular regulation.

Purpose of the Study:

  • To investigate the protective effects of angiotensin-(1-7) [ANG-(1-7)] and its nonpeptide analog AVE-0991 against diabetes-induced cardiovascular dysfunction.
  • To assess the impact of ANG-(1-7) and AVE-0991 on proteinuria, vascular reactivity, and cardiac recovery from ischemia-reperfusion in a diabetic rat model.

Main Methods:

  • Streptozotocin-induced diabetic rats were treated with ANG-(1-7) or AVE-0991 for 4 weeks.
  • Evaluated proteinuria, vascular responsiveness to vasoactive agonists in isolated arteries and mesenteric beds.
  • Assessed cardiac recovery from ischemia-reperfusion in isolated perfused hearts.

Main Results:

  • Diabetes significantly increased proteinuria, which was reduced by ANG-(1-7) and AVE-0991 treatment.
  • Both treatments prevented diabetes-induced abnormal vascular responsiveness to various agonists.
  • Cardiac function recovery from ischemia-reperfusion was significantly improved in treated diabetic rats.

Conclusions:

  • Activation of angiotensin-(1-7) [ANG-(1-7)]-mediated pathways confers protection against diabetes-induced cardiovascular dysfunction.
  • ANG-(1-7) and AVE-0991 demonstrate therapeutic potential for mitigating cardiovascular complications in diabetes.
  • Targeting ANG-(1-7) signaling represents a promising strategy for managing cardiovascular events in diabetic patients.

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...